Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
17.44 USD | +43.07% | +49.57% | +59.27% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | 800K | Capitalization | 627M |
---|---|---|---|---|---|
Net income 2024 * | -182M | Net income 2025 * | -264M | EV / Sales 2024 * | - |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 784 x |
P/E ratio 2024 * |
-4.78
x | P/E ratio 2025 * |
-2.8
x | Employees | 157 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.29% |
Latest transcript on iTeos Therapeutics, Inc.
1 day | +43.07% | ||
1 week | +49.57% | ||
Current month | +62.38% | ||
1 month | +42.48% | ||
3 months | +62.69% | ||
6 months | +82.43% | ||
Current year | +59.27% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Detheux
FOU | Founder | 57 | 12-03-31 |
Matthew Gall
DFI | Director of Finance/CFO | 47 | 20-05-31 |
Yvonne McGrath
CTO | Chief Tech/Sci/R&D Officer | 50 | 20-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Ann Rhoads
BRD | Director/Board Member | 58 | 20-05-31 |
David Hallal
CHM | Chairman | 57 | 18-05-31 |
Director/Board Member | 52 | 18-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.13% | 0 M€ | -1.57% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 17.44 | +43.07% | 5,259,062 |
24-05-09 | 12.19 | -0.08% | 84,546 |
24-05-08 | 12.2 | -0.89% | 146,984 |
24-05-07 | 12.31 | -0.81% | 296,759 |
24-05-06 | 12.41 | +6.43% | 303,970 |
Delayed Quote Nasdaq, May 10, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+59.27% | 627M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- ITOS Stock